Bio-Rad Laboratories, Inc. (NYSE:BIO) EVP John Hertia sold 5,195 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $336.57, for a total transaction of $1,748,481.15. Following the completion of the transaction, the executive vice president now directly owns 15,507 shares in the company, valued at $5,219,190.99. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
John Hertia also recently made the following trade(s):
- On Monday, September 9th, John Hertia sold 444 shares of Bio-Rad Laboratories stock. The stock was sold at an average price of $336.47, for a total transaction of $149,392.68.
Shares of Bio-Rad Laboratories stock opened at $326.42 on Thursday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.36 and a current ratio of 4.68. The firm has a 50-day moving average of $329.75 and a 200-day moving average of $309.28. Bio-Rad Laboratories, Inc. has a 52-week low of $220.05 and a 52-week high of $345.50. The stock has a market cap of $10.00 billion, a PE ratio of 55.89, a PEG ratio of 3.11 and a beta of 1.18.
A number of equities research analysts have recently issued reports on the company. Barclays boosted their price objective on Bio-Rad Laboratories from $350.00 to $380.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. They noted that the move was a valuation call. Goldman Sachs Group upgraded Bio-Rad Laboratories from a “buy” rating to a “conviction-buy” rating and set a $400.00 target price on the stock in a research note on Tuesday, August 20th. Finally, ValuEngine cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $378.33.
Several large investors have recently made changes to their positions in the business. BlackRock Inc. raised its position in shares of Bio-Rad Laboratories by 1.2% in the second quarter. BlackRock Inc. now owns 1,950,805 shares of the medical research company’s stock valued at $609,803,000 after buying an additional 22,263 shares in the last quarter. Royal Bank of Canada grew its position in Bio-Rad Laboratories by 13.6% during the second quarter. Royal Bank of Canada now owns 6,677 shares of the medical research company’s stock worth $2,086,000 after buying an additional 798 shares in the last quarter. Verition Fund Management LLC bought a new position in Bio-Rad Laboratories during the 2nd quarter worth $679,000. Amundi Pioneer Asset Management Inc. bought a new position in Bio-Rad Laboratories during the 2nd quarter worth $679,000. Finally, Zacks Investment Management increased its stake in Bio-Rad Laboratories by 469.5% during the 2nd quarter. Zacks Investment Management now owns 4,237 shares of the medical research company’s stock worth $1,325,000 after acquiring an additional 3,493 shares during the period. Hedge funds and other institutional investors own 62.46% of the company’s stock.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.
Recommended Story: What is a balanced fund?
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.